Fan Guoqiang, Qiao Yu, Gao Shixing, Guo Jun, Zhao Ruqian, Yang Xiaojing
Key Laboratory of Animal Physiology & Biochemistry, Nanjing Agricultural University, Nanjing, P. R. China.
Horm Metab Res. 2017 Oct;49(10):793-800. doi: 10.1055/s-0043-118910. Epub 2017 Sep 21.
Zinc alpha2 glycoprotein (ZAG) is a new type of adipokine involved in adipose tissue mobilization, however, little is known about its lipid metabolism effect in liver. Therefore, we investigated the effects of ZAG in the regulation of hepatic lipid accumulation. Mice were randomly divided into two groups; one was fed a normal diet and another was fed a high-fat diet for eight weeks to establish obesity model. After that, the normal diet group was divided into ND (injection of pcDNA3.1) and NDZ (injection of ZAG recombinant plasmid) and the high-fat diet group was divided into HF (injection of pcDNA3.1) and HFZ (injection of ZAG recombinant plasmid). The mice were weighed once per week and injected with plasmid once every three days for eight times. The results showed that body weight and hepatic TG content were decreased dramatically in HFZ group compared with HF group. The stearoyl-CoAdesaturase1 (SCD1) and Acyl-CoA Synthetase-1 (ACSS1) protein levels in HFZ group were significantly decreased. Furthermore, phosphorylated hormone sensitive lipase (P-HSL) was significantly higher in HFZ group. In HFZ group, hepatic fatty acid translocase (CD36) and fatty acids binding protein-1 (FABP1) protein levels were reduced. In addition, the expression of phosphorylated protein kinase A (PPKA) in HFZ group was higher than the HF group. Meanwhile, NDZ group showed significantly decreased body weight and increased P-HSL level though the hepatic TG content showed no significantly changes compared with the ND group. Therefore, we conclude that ZAG may be beneficial for preventing high-fat-diet-induced hepatic lipid metabolic disorders.
锌α2糖蛋白（ZAG）是一种参与脂肪组织动员的新型脂肪因子，然而，其对肝脏脂质代谢的影响却知之甚少。因此，我们研究了ZAG在调节肝脏脂质积累中的作用。将小鼠随机分为两组；一组给予正常饮食，另一组给予高脂饮食八周以建立肥胖模型。之后，正常饮食组分为ND（注射pcDNA3.1）和NDZ（注射ZAG重组质粒），高脂饮食组分为HF（注射pcDNA3.1）和HFZ（注射ZAG重组质粒）。每周称一次小鼠体重，每三天注射一次质粒，共注射八次。结果显示，与HF组相比，HFZ组的体重和肝脏TG含量显著降低。HFZ组的硬脂酰辅酶A去饱和酶1（SCD1）和酰基辅酶A合成酶-1（ACSS1）蛋白水平显著降低。此外，HFZ组中磷酸化激素敏感性脂肪酶（P-HSL）显著升高。在HFZ组中，肝脏脂肪酸转运蛋白（CD36）和脂肪酸结合蛋白-1（FABP1）蛋白水平降低。此外，HFZ组中磷酸化蛋白激酶A（PPKA）的表达高于HF组。同时，NDZ组体重显著降低，P-HSL水平升高，尽管与ND组相比肝脏TG含量无显著变化。因此，我们得出结论，ZAG可能有助于预防高脂饮食诱导的肝脏脂质代谢紊乱。
